elpasojet, we are pretty much on the same page so far as this possible scenario is concerned. I agree that those who control the price which I have been calling the Big Boys have a very significant position and possibly operating stealthily with the same objective prior to the NG information becoming public. I am not certain about the pace of the future revelations and developments and despite considering this scenario as a real possibility, I have not yet abandoned my views concerning the management. The probability of this scenario as a real possibility will rise significantly once the management adopts measures in an attempt to raise shareholder value which are contrary to its past attitude and behavior. So the " pleasant surprise" you mention and are expecting " in the upcoming reporting of the survey and estimate reserve value of those NG" would be a clear indication in this direction; and it will also explain the past behavior. We have only several weeks left to find out.
ARIA true longs knew AP26113's 10-fold potency 4 years ago. That's why the real saturnxyz is attacked & impersonated by saturmxyz.
The imposter basher virus impersonates and attacks every Ariad true long filthily. He impersonates joyakid with joyokid and joyakld filthily, so joyakid had to leave this YMB board and move to iHub. The virus still attacks and impersonate joyakid even though the nice lady has left this board for years
Sentiment: Strong Buy
Companies who want to expand into a product space either grow their own brand or buy another product line to instantly increase their market share. For RMH to be a valuable buy out candidate, it needs to have at least it's domestic distribution intact in most/all states with a number of quarters of good sales numbers.
Patent protection doesn't mean a thing (unless you watch Shark Tank) and neither does competition in a new space. Hemp drinks are a new space so it won't stop the big beverage companies from entering it and buying out an existing product line is an option. Who knows if that's an option here. At this rate of 1-2 states a week added for distribution, it may take a while before they get the entire country covered.
Silly pumping....after de Dva news tomorrow, we might end up at 30c. But of course, I hope good news is on our way. But this is a gambling stock at this point
Don't bother, it was a setup by new appointed managers at the time ( Williamson and Hanston) that backfired badly. Unfortunately STZ backed then up to cover other sins ever since.
I've been told over and over again that when Cartiform is used in a hospital setting, insurance approvals are not required. Its covered as long as the doctor prescribes its use. Insurance coverage is required only if the procedure would be preformed in clinics and doctors offices and at the present, that is not being done.
You think they will have $697 million in sales in the second half of 2016? That's quite a stretch. Even Matt says no profit from Afrezza sales until 2016 or was it 2017?
Sounds like someone who needs to keep the price low to cover their shorts and their a$$ests. Or are you an a$$hat ? No volume as the longs don't want to sell to the shorts when they are trying to cover. You keep bringing up quarters, losses and failures. I am sure YOUR publicly traded company is doing marvelous...... La-hoo.... Sa-herrrrs.
Sentiment: Strong Buy
I would be shocked if any analyst ever would cover this stock.
There is no money to be made by Wall St. having an analyst covering a small, profitable company such as this with only 3 million shares outstanding. There is more money to be made by deploying those analysts to offer rosy outlooks on money-losing internet and biotech stocks.
One doesn't need an analyst to see how extreme OTEL's stock price has become. Here is a basic comparison with one of OTEL's peers. NULM operates in the Midwest in the same biz as OTEL, but without cloud hosting to my knowledge. It has no analyst coverage.
Trailing Twelve Month EBITDA:
OTEL: $28.7 million
NULM: $14.4 million
OTEL: $121.2 million
NULM: $76.9 million
OTEL's trailing twelve month EBITDA is approximately twice that of NULM. If the Market would assign a similar value to OTEL (around 5.3x TTM EBITDA) OTEL's Enterprise Value would be around $152 million. Subtract OTEL's $107 million in net debt from $152 million and you get $45 million in equity value. OTEL's equity currently is valued at $14 million. If OTEL's equity value would magically triple here, it still would be valued lower than NULM at this point.
ray I cant tell U what to do w/ EXEL..Ive been long for years and Ive played the swings UP and DOWN and I ve posted on it ad nauseum..even MBB has given me grief over it...but it is what it is..they have great Science but they spend money FAST and FURIOUS...that seems to be in better control now..heres a blurb on MF about that controlled spending and they surprised on the upside for Q1 so if you have money to commit..this may be the right time?
[What: Shares of Exelixis , a biopharmaceutical company engaged in research to develop novel cancer drugs, surged 14% in intraday trading on Friday after announcing better-than-expected first-quarter earnings results.
So what: For the quarter, Exelixis produced revenue of $9.4 million from the sale of Cometriq as a treatment for metastatic medullary thyroid cancer, a 91% increase from its sales in Q1 2014.
On the flipside, expenses plunged as research and development costs dipped to $22.3 million from $54.8 million in the comparable period, and selling, general, and administrative expenses dropped by more than $5 million. Overall, Exelixis' net loss was $0.18 per share, considerably better than the $0.39 per share loss reported in the year-ago period. Comparably speaking, Wall Street was expecting revenue of closer to $8 million and a loss of $0.24 per share, so this was a sizable beat all around.
Exelixis announced it ended the quarter with $197.6 million in cash and cash equivalents, down from $242.8 million in the sequential fourth-quarter. The company anticipates operating expenses for the first-half of this year will total $70 million to $80 million.
Now what: Beyond the numbers there were also two intriguing tidbits in Exelixis' quarterly results.
First, the company's press release states that it'll be presenting 14 total posters at the American Society of Clinical Oncology's annual meeting, including eight posters on Cometriq and six of cobimetinib.